[1] |
Nagore E, Heidenreich B, Rachakonda S, et al. TERT promoter mutations in melanoma survival[J]. Int J Cancer, 2016,139(1):75⁃84. doi: 10.1002/ijc.30042.
|
[2] |
Leão R, Apolónio JD, Lee D, et al. Mechanisms of human telomerase reverse transcriptase (hTERT) regulation: clinical impacts in cancer[J]. J Biomed Sci, 2018,25(1):22. doi: 10. 1186/s12929⁃018⁃0422⁃8.
|
[3] |
Bai X, Kong Y, Chi Z, et al. MAPK pathway and TERT promoter gene mutation pattern and its prognostic value in melanoma patients: a retrospective study of 2,793 cases[J]. Clin Cancer Res, 2017,23(20):6120⁃6127. doi: 10.1158/1078⁃0432.CCR⁃17⁃0980.
|
[4] |
Kang XJ, Shi XH, Chen WJ, et al. Analysis of KIT mutations and c⁃KIT expression in Chinese Uyghur and Han patients with melanoma[J]. Clin Exp Dermatol, 2016,41(1):81⁃87. doi: 10. 1111/ced.12659.
|
[5] |
Viana⁃Pereira M, Almeida GC, Stavale JN, et al. Study of hTERT and histone 3 mutations in medulloblastoma[J]. Pathobiology, 2017,84(2):108⁃113. doi: 10.1159/000448922.
|
[6] |
曾颖, 康晓静, 张祥月, 等. 肢端型黑素瘤NRAS基因突变检测及预后分析[J]. 中华皮肤科杂志, 2016,49(7):474⁃477. doi: 10.3760/cma.j.issn.0412⁃4030.2016.07.006.
|
[7] |
Zhang N, Wang L, Zhu GN, et al. The association between trauma and melanoma in the Chinese population: a retrospective study[J]. J Eur Acad Dermatol Venereol, 2014,28(5):597⁃603. doi: 10.1111/jdv.12141.
|
[8] |
耿怡. 368例原发性皮肤恶性黑素瘤的临床、病理特征及预后分析[D]. 北京: 北京协和医学院, 2018.
|
[9] |
Chi Z, Li S, Sheng X, et al. Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases[J]. BMC Cancer, 2011,11:85. doi: 10. 1186/1471⁃2407⁃11⁃85.
|
[10] |
孙东杰, 高天文, 李春英, 等. 西安、重庆两所医院20年皮肤恶性黑素瘤回顾[J]. 中华皮肤科杂志, 2004,(2):37⁃39.
|
[11] |
Watts CG, Madronio C, Morton RL, et al. Clinical features associated with individuals at higher risk of melanoma: a population⁃based study[J]. JAMA Dermatol, 2017,153(1):23⁃29. doi: 10.1001/jamadermatol.2016.3327.
|
[12] |
Tannous ZS, Mihm MC Jr, Sober AJ, et al. Congenital melanocytic nevi: clinical and histopathologic features, risk of melanoma, and clinical management[J]. J Am Acad Dermatol, 2005,52(2):197⁃203. doi: 10.1016/j.jaad.2004.07.020.
|
[13] |
Dika E, Veronesi G, Altimari A, et al. BRAF, KIT, and NRAS mutations of acral melanoma in white patients[J]. Am J Clin Pathol, 2020,153(5):664⁃671. doi: 10.1093/ajcp/aqz209.
|
[14] |
Birkeland E, Zhang S, Poduval D, et al. Patterns of genomic evolution in advanced melanoma[J]. Nat Commun, 2018,9(1):2665. doi: 10.1038/s41467⁃018⁃05063⁃1.
|
[15] |
Luo Y, Zhang Z, Liu J, et al. Characterizations of gene alterations in melanoma patients from Chinese Population[J]. Biomed Res Int, 2020,2020:6096814. doi: 10.1155/2020/6096814.
|
[16] |
任敏, 孔蕴毅, 沈旭霞, 等. 黑色素瘤中BRAF基因突变检测及其与临床病理特征的相关性[J]. 中华病理学杂志, 2020,49(6):610⁃612. doi: 10.3760/cma.j.cn112151⁃20191012⁃00556.
|
[17] |
郭芳, 康晓静, 唐小辉, 等. 新疆80例恶性黑素瘤BRAF基因突变分析[J]. 中华皮肤科杂志, 2013,46(1):33⁃36. doi: 10. 3760/cma.j.issn.0412⁃4030.2013.01.013.
|
[18] |
Huang FW, Hodis E, Xu MJ, et al. Highly recurrent TERT promoter mutations in human melanoma[J]. Science, 2013,339(6122):957⁃959. doi: 10.1126/science.1229259.
|
[19] |
Colombino M, Capone M, Lissia A, et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma[J]. J Clin Oncol, 2012,30(20):2522⁃2529. doi: 10.1200/JCO.2011.41.2452.
|
[20] |
Jakob JA, Bassett RL Jr, Ng CS, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma[J]. Cancer, 2012,118(16):4014⁃4023. doi: 10.1002/cncr.26724.
|